Fall ’21 Winter ’22 COVID

Fall ’21 Winter ’22 COVID

The disease continued to ravage everywhere, though there seemed to be zones of relatively less contagion where most people had chosen to get the vaccination.  In places where people continued to refuse or at least hesitate to get the effective vaccination choices, hospitals were overwhelmed.

October 1, 2021:  Merck and Ridgeback Biotherapeutics said their results (still not peer-reviewed) demonstrate their novel drug molnupiravir cut in half the rate of hospitalization and death in persons with mild to moderate disease. If authorized by the US Food and Drug Administration for emergency use, the pill would become the first oral medicine to fight viral infection for Covid-19. [CNN article]

3,898,466 COVID Deaths Worldwide

October 2, 2021: 235,399,322 cases; 4,810,952 deaths worldwide

719,674 COVID Deaths USA

October 2, 2021: 44,491,504 cases; 719,674 deaths in the US

% Vaccinated (+18 old) USA

October 2, 2021: 64.6% at least once; 66.9 % both

US COVID Decline

October 11, 2021: the number of Covid-19 cases in the US continued to fall infections and hospitalizations declined. The average rate of daily new cases has dropped below 100,000, to 93,814 as of October 10, according to data from Johns Hopkins University.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases said he would like to see new daily cases well below 10,000, but the decline was a start. “Hopefully it’s going to continue to go in that trajectory downward,” he said. [CNN article]

Merck/Molnupiravir

October 11, 2021: Merck said that it had submitted an application to the Food and Drug Administration to authorize what would be the first antiviral pill to treat Covid.

An approval for the drug, molnupiravir, would be a milestone in the fight against the coronavirus, experts said, because a convenient, relatively inexpensive treatment could reach many more high-risk people sick with Covid than the cumbersome antibody treatments currently being used. [NYT article]

4,913,952 COVID Deaths Worldwide

October 17, 2021: 241,456,533 cases; 4,913,952 deaths worldwide

744,546 COVID Deaths USA

October 17, 2021: 45,792,532 cases; 744,546 deaths in the US

% Vaccinated (+18 old) USA

October 17, 2021: 65.9% at least once; 684 % fully

Cold Weather Effect

October 18, 2021: the NY Times reported that even as the Delta-variant-driven virus wave was receding in much of the United States, many counties across the country’s northernmost regions were experiencing rising cases as colder weather arrived.

The top five states in new daily cases per capita were led by Alaska, which was logging the highest daily average: 125 cases per 100,000 people, according to a New York Times database. The next four states, with at least 67 cases per 100,000 people, were MontanaWyomingNorth Dakota and Idaho.

Cases were at least trending downward or holding steady in those states. The five states with the fastest rising caseloads were Vermont, Colorado, New Hampshire, Michigan and Minnesota, and the two counties with the most cases per capita in Vermont and New Hampshire were on the Canadian border.

US Falls Behind

October 24, 2021: the NY Times reported that the United States was one of the first countries to begin vaccinating its population, and by summer 2021, was leading most nations in getting shots in arms, with 67 percent of the population receiving at least one shot by July 4, 2021.

By October 2021, the United States,  despite having a surplus of doses, had fully vaccinated only 57 percent of its population, according to a New York Time tracker. Resistance remained high among some demographic groups and within some specific work force sectors, including police officers and firefighters.

That left the United States lagging behind dozens of nations in the pursuit of full vaccination. Although, with a population of about 330 million, it ranks third in the sheer number of administered doses, more than 411 million, after China’s more than 2.2 billion doses and India’s more than one billion.

 

Previous and subsequent COVID-19 posts:
Thanks for visiting

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.